Document is current
Any future updates will be listed below
-
Authors
Muro, Shigeo http://orcid.org/0000-0001-7452-9191
Kawayama, Tomotaka
Sugiura, Hisatoshi
Seki, Munehiro
Duncan, Elizabeth A.
Bowen, Karin
Marshall, Jonathan
Megally, Ayman
Patel, Mehul http://orcid.org/0000-0003-0435-858X
-
Funding
Funding for this research was provided by:
AstraZeneca (N/A, N/A, N/A, N/A, N/A, N/A)
- License Information
-
More Information
Article History
Received: 28 March 2024
Accepted: 17 July 2024
First Online: 5 August 2024
Declarations
:
: The study was conducted in accordance with Good Clinical Practice, including the Declaration of Helsinki. The protocol and informed consent form were approved by appropriate institutional review boards or independent ethics committees prior to the start of the study (a full listing of appropriate institutional review boards or independent ethics committees has been published []). All patients provided written informed consent before screening.
: Not applicable.
: SM has received lecture fees from AstraZeneca, GlaxoSmithKline, Nippon Boehringer Ingelheim, and Novartis Pharma. TK has received grants from Helios co. Ltd. and lecture fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Kyorin, Novartis, Sanofi, and Teijin healthcare. HS has received lecture fees from AstraZeneca, GlaxoSmithKline, Nippon Boehringer Ingelheim, Novartis Pharma, and Sanofi. MS is an employee of AstraZeneca K.K. Kita-ku and owns stock and/or stock options in the company. EAD is a former employee of AstraZeneca and owns stock and/or stock options in the company. KB, JM, AM, and MP are employees of AstraZeneca and own stock and/or stock options in the company.
